in vitro sensitivity-directed chemotherapy

DRUG3 trials

Sponsors

Swiss Cancer Institute, Children's Oncology Group, University of Washington

Conditions

LeukemiaOvarian CancerRecurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid Leukemia

Phase 3

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

CompletedNCT00003214

Swiss Cancer InstituteOvarian Cancer

Start: 1996-07-31End: 2000-04-30Target: 300Updated: 2019-05-15

Unknown Phase

Cell Samples From Patients With Leukemia

CompletedNCT01395628

Children's Oncology GroupLeukemia

Start: 2011-07-31Target: 10Updated: 2016-05-19

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

CompletedNCT02551718

University of WashingtonRecurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia +3

Start: 2015-09-11End: 2021-05-13Updated: 2022-06-30

Related Papers

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Blood2022-11-153 citations

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood2019-11-132 citations

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood2016-12-02